The Safety Profile of Amivantamab and Lazertinib in EGFR-Mutant NSCLC
Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses the safety profile of amivantamab and lazertinib in EGFR-mutated non-small cell lung cancer, based on data from the CHRYSALIS tria.
Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses the safety profile of amivantamab and lazertinib in EGFR-mutated non-small cell lung cancer (NSCLC), based on data from the CHRYSALIS trial (NCT02609776) presented at the 2021 American Society of Clinical Oncology Annual Meeting.
According to Spira, the safety profile of the combination is very different from chemotherapy. The major adverse events include rash and diarrhea. Additionally, amivantamab may cause infusion-related toxicities. However, according to Spira, the combination in well tolerated.
Changes in patients’ nails and hair are also common with the combination. Most infusion-related reactions occur in the first day, according to Spira, and generally do not continue for much longer.
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
FDA Grants Breakthrough Therapy Designation to Sunvozertinib in EGFR Exon20+ NSCLC
April 9th 2024Sunvozertinib was granted breakthrough therapy designation by the FDA for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer harboring an EGFR exon 20 insertion mutation.
Read More
